Enoxaparin (Lovenox)
What studies of Enoxaparin (Lovenox) found
At a glance, by condition
Preventing long COVID: B May help
Based on the strongest evidence, the randomised trial (low certainty): 2 findings, all B.
7 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Enoxaparin (Lovenox) may help for preventing long COVID, but the evidence is still limited. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- Enoxaparin (Lovenox) · Preventing long COVID is hereBMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Preventing long COVID
Symptoms
Anxiety1 study · 218 people took Enoxaparin (Lovenox) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight.
The randomised trial439 randomised · for a total of 14 days · 40 mg, once daily for 14 days
Anxiety improved more than in the comparison group.
Enoxaparin (Lovenox) may reduce anxiety later, when given during acute COVID. Improvement · low certainty B
- High risk of bias (RoB 2) in the results that carry most of the weight
See the 1 study
-
- People in the study
- 439 randomised
- Dose
- 40 mg, once daily for 14 days
- Outcome
- EQ-5D-5L dimensions EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
- Effect
- better (not tested)
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- High
Autonomic symptoms1 study · 218 people took Enoxaparin (Lovenox) Improvement B
Why this grade: Improvement, low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight.
The randomised trial439 randomised · for a total of 14 days · 40 mg, once daily for 14 days
Autonomic symptoms improved more than in the comparison group.
Enoxaparin (Lovenox) may reduce autonomic symptoms later, when given during acute COVID. Improvement · low certainty B
- High risk of bias (RoB 2) in the results that carry most of the weight
See the 1 study
-
- People in the study
- 439 randomised
- Dose
- 40 mg, once daily for 14 days
- Outcome
- Palpitations
- Effect
- better (not tested)
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Pain1 study · 218 people took Enoxaparin (Lovenox) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; no confidence interval shows an important benefit is ruled out.
The randomised trial439 randomised · for a total of 14 days · 40 mg, once daily for 14 days
No clear difference in pain.
The evidence is very uncertain about the effect of enoxaparin (Lovenox) on pain later, when given during acute COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- No confidence interval shows an important benefit is ruled out
See the 1 study
-
- People in the study
- 439 randomised
- Dose
- 40 mg, once daily for 14 days
- Outcome
- Abdominal pain
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Sleep1 study · 218 people took Enoxaparin (Lovenox) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; no confidence interval shows an important benefit is ruled out.
The randomised trial439 randomised · for a total of 14 days · 40 mg, once daily for 14 days
No clear difference in sleep.
The evidence is very uncertain about the effect of enoxaparin (Lovenox) on sleep later, when given during acute COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- No confidence interval shows an important benefit is ruled out
See the 1 study
-
- People in the study
- 439 randomised
- Dose
- 40 mg, once daily for 14 days
- Outcome
- Sleeping disorders
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Breathlessness1 study · 218 people took Enoxaparin (Lovenox) Uncertain –
Why this grade: Uncertain, low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one study saw it get worse, without a test against chance.
The randomised trial439 randomised · for a total of 14 days · 40 mg, once daily for 14 days
Too little to say about breathlessness.
Too little to say: breathlessness got worse in one study, but the change wasn't tested against chance. Uncertain · low certainty –
- High risk of bias (RoB 2) in the results that carry most of the weight
- One study saw it get worse, without a test against chance
See the 1 study
-
- People in the study
- 439 randomised
- Dose
- 40 mg, once daily for 14 days
- Outcome
- Dyspnea
- Effect
- worse (not tested)
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Daily life and health overall
Daily functioning1 study · 218 people took Enoxaparin (Lovenox) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; no confidence interval shows an important benefit is ruled out.
The randomised trial439 randomised · for a total of 14 days · 40 mg, once daily for 14 days
No clear difference in daily functioning.
The evidence is very uncertain about the effect of enoxaparin (Lovenox) on daily functioning later, when given during acute COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- No confidence interval shows an important benefit is ruled out
See the 1 study
-
- People in the study
- 439 randomised
- Dose
- 40 mg, once daily for 14 days
- Outcome
- PCFS grade 1 to 3 Post–COVID-19 Functional Status
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Quality of life1 study · 218 people took Enoxaparin (Lovenox) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; no confidence interval shows an important benefit is ruled out.
The randomised trial439 randomised · for a total of 14 days · 40 mg, once daily for 14 days
No clear difference in quality of life.
The evidence is very uncertain about the effect of enoxaparin (Lovenox) on quality of life later, when given during acute COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- No confidence interval shows an important benefit is ruled out
See the 1 study
-
- People in the study
- 439 randomised
- Dose
- 40 mg, once daily for 14 days
- Outcome
- EQ-VAS EuroQol visual analog scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
1 to 40 mg at the start
- 2Top dose
Most often 1 mg (1 of 2 studies)
Doses across 2 studies
1 to 40 mg.
Each study’s dose, as printed
- 40 mg, once daily for 14 days Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial. (2024)
- 1 mg/kg daily Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. (2022)
All papers
- Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.2024 · randomised trial · 439 randomised
Summary
The Post-OVID study followed participants from the OVID randomized, open-label, controlled trial of outpatients older than 50 years with acute COVID-19. Of 469 eligible patients, 439 participated at 6 centers; 218 were in the enoxaparin group and 221 in the control group. The enoxaparin group received subcutaneous enoxaparin 40 mg once daily for 14 days; the control group received no treatment (standard of care). Mean follow-up was 24 (SD, 4) months. Outcomes included hospitalization and death, cardiovascular events, long COVID symptoms, Post–COVID-19 Functional Status (PCFS), and EuroQol scales. Between 90 days and 24 months, hospitalization and death occurred in 18 (8.3%) vs 22 (9.9%) patients (relative risk, 0.83; 95% CI, 0.5-1.5; P = .5); the abstract reports 10% in controls. Cardiovascular events occurred in 4 (1.8%) vs 3 (1.4%) (relative risk, 1.35; 95% CI, 0.31-5.97). Long COVID symptoms were reported by 44% vs 47%; any symptom by 95 (44) vs 103 (47). PCFS grade 1 to 3 was recorded in 15% in each group (odds ratio, 0.98; 95% CI, 0.6-1.7; P > .99), and no patients reported PCFS grade 4. Median EQ-VAS was 85 in both groups (IQR, 80-90 for standard of care and 75-90 for enoxaparin). Harms and withdrawals for harms were not reported.
- Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes.2022 · randomised trial · 375 randomised
Summary
This randomized clinical trial compared intermediate-dose with standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to intensive care in 10 academic centers in Tabriz and Tehran, Iran, and assessed post-COVID functional limitation and depressive symptoms. Of 375 included patients (median age 62 years; 42% women), 187 were assigned intermediate-dose enoxaparin 1 mg/kg daily and 188 standard-dose enoxaparin 40 mg daily, continued until 30 days from randomization or death or a thrombotic or hemorrhagic event. Functional status was measured with the Post-COVID-19 functional status scale (PCFS) and depressive symptoms with the Patient Health Questionnaire-2 (PHQ-2) at 30-day and 90-day follow-up. At 90 days, PCFS grade 3-or-4 was 10/187 (5.3%) with intermediate-dose versus 8/188 (4.2%) with standard-dose (OR 1.20, 95% CI 0.46–3.11; P=0.80), and PHQ-2 ≥3 was 16/89 (17.9%) versus 14/91 (15.3%) (OR 1.14, 95% CI 0.79–1.65; P=0.14). In the pooled cohort, PCFS grade 3-or-4 decreased from 20.0% to 4.8% (P<0.001), PCFS grade 0 increased from 4.2% to 15.4% (P<0.001), median PHQ-2 declined from 2 (IQR 0–3) to 0 (IQR 0–2) (P<0.001), and PHQ-2 ≥3 decreased from 47/180 (26.1%) to 30/180 (16.6%) (P=0.05). Deaths were 191/375 (50.9%) by 30 days and 195/375 (52.0%) by 90 days; by treatment arm, 98 and 97 patients died. Harms were not reported. The authors state limitations including 103 patients who did not agree to participate and unknown pre-COVID-19 functional and mood status.
- Effect of Respiratory and Anticoagulation Medications on Long Covid in the Postpartum Period2023 · compared with another group · 444 in the study
Summary
This multi-center, prospective observational study compared all pregnant women diagnosed with SARS-CoV-2 infection in the 3rd trimester through 6 weeks postpartum. The study included 444 patients diagnosed with LC. Primary outcomes were patient-reported symptoms and provider interpretation in the immediate postpartum, 1-week postpartum (1P), and 6-week postpartum (6P) periods. Treatments examined included enoxaparin, aspirin 325mg, theophylline, and antiviral therapies. 291 (65.6%) patients received enoxaparin at time of diagnosis continued weekly until 6 weeks postpartum. Patients who received enoxaparin were less likely to report LC at the 1P and 6P visits (39.2% v. 54.9%, p = 0.02). LC was not significantly different when comparing patients who received antiviral therapies to those who did not. Patients with LC were more likely to report improvement when taking aspirin 325mg (19.8% v. 11.3%, p = 0.003) or when taking theophylline (22.9% v. 14.2%, p = 0.01). After adjusting for confounding factors these differences remained significant. Side effects, harms, worsening and stopping treatment were not reported. The authors do not state limitations in the provided text.
- The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.2021 · combination: given with other treatments · 50 in the study · 30 with outcome data
Summary
This paper reports preliminary data from the authors’ Institute and clinical cases. 50 patients were consecutively enrolled from 1 May 2021 to 30 June 2021 for symptoms including dyspnea, fatigue, cough, headache, loss of appetite and myalgia; of the patients enrolled, thirty recovered from COVID-19. The paper also reports a 45-year-old male hospitalized for SARS-CoV-2 positivity and a 71-year-old man with Long-COVID. The 45-year-old received enoxaparin 4000 UI 0,4 subcutaneous bid; Anti-platelet factor 4 (PF4) was present and enoxaparin was stopped; the paper reports a COVID-19 patient who developed DIC after enoxaparin administration, and worsening was observed on the second day of hospitalization (MEWS 8). Rivaroxaban 15 mg bid was started; on the seventh day coagulation parameters were normalized (DIC score = 0) and clinical conditions improved with MEWS score 0, and rapid remission of symptoms and normalization of hematochemical parameters occurred after withdrawal of enoxaparin. The 71-year-old received CPAP for 10 days during acute COVID-19 and later ceftriaxone and enoxaparin; after six days of therapy his clinical condition and laboratory parameters improved. At discharge he received rivaroxaban 2.5 mg bid and atorvastatin 40 mg die. For the long-COVID group, no differences were found in demographics, medical history and vital signs compared to no COVID-19 patients.